Jim Cassella

Jim Cassella

Company: Concert Pharmaceuticals

Job title: Chief Development Officer

Seminars:

Speaker Q&A panel 1:10 pm

Read more

day: Day Two

Update on Long-Term Safety & Efficacy of CTP-543, an Oral JAK Inhibitor, for the Treatment of Alopecia Areata 11:55 am

CTP-543 was dosed for 24 weeks in three Phase 2 trials; eligible patients subsequently enrolled in a long-term, open-label extension trial with >130 patients treated for more than 1 year. Hair regrowth assessed by SALT has been sustained or improved in the vast majority of patients in the extension study relative to the Phase 2…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.